Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future...

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in breast cancer (BC) therapy.
• ADCs combine targeted antibody delivery with potent cytotoxic agents to improve efficacy and reduce systemic toxicity.

Purpose of the Study:

• To review recent innovations in ADC development for breast cancer.
• To discuss persistent challenges and future directions in ADC therapy.

Main Methods:

• Review of current literature on ADC design, targets, and therapeutic strategies.
• Analysis of advancements in payload, linker, and antibody engineering.
• Exploration of emerging technologies like AI/ML in ADC development.

Main Results:

• Novel ADC designs target antigens like HER2, HER3, and CD276, showing potent anti-tumor activity.
• New delivery strategies, dual-payloads, and sequential therapies enhance precision oncology.
• AI and machine learning are accelerating ADC design and patient stratification.

Conclusions:

• ADCs offer a powerful therapeutic modality for breast cancer, with ongoing innovations addressing efficacy and safety.
• Overcoming challenges such as tumor heterogeneity and drug resistance is crucial for maximizing ADC benefits.
• Future ADC development will likely involve advanced engineering, AI integration, and personalized treatment approaches.